On February 27, 2008, the Tarrytown, New York-based Regeneron Pharmaceuticals received approval for Arcalyst (rilonacept), a treatment for cryopyrin-associated periodic syndromes (CAPS), including ...

On February 27, 2008, the Tarrytown, New York-based Regeneron Pharmaceuticals received approval for Arcalyst (rilonacept), a treatment for cryopyrin-associated periodic syndromes (CAPS), including ...

Kiniksa Pharmaceuticals arguably has a gold mine with its recurrent pericarditis drug Arcalyst. Many investors view the healthcare sector as a safe haven when the stock market is turbulent.

The sudden rise in the share price can be attributed to the positive investor expectations regarding the continued strong sales growth of Kiniksa’s only approved drug, Arcalyst (rilonacept).